Atrial fibrillation is an important cause of preventable, disabling stroke and is particularly
frequent in patients with chronic kidney disease (CKD). Stage 3 CKD is an independent risk …

Background Oral anticoagulation therapy with warfarin or direct oral anticoagulants
(DOACs) is the mainstay for stroke prevention in patients with non‐valvular atrial fibrillation …

Randhawa and colleagues1 report the results of an updated meta-analysis of 15
observational studies reporting the outcomes of 47 480 patients with atrial fibrillation (AF) …

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) depend on some
degree of renal excretion, and no head-to-head comparisons based on renal function is …

Background Concomitant atrial fibrillation and end‐stage renal disease is common and
associated with an unfavorable prognosis. Although oral anticoagulants have been well …

Background Treatment with vitamin K antagonists (VKAs) has been linked to worsening of
kidney function in patients with atrial fibrillation (AF). Objectives XARENO (Factor XA …

Importance In the Apixaban for Reduction of Stroke and Other Thromboembolic
Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 …

Background: Edoxaban is a novel oral anticoagulant which may decrease the risk of stroke
and systemic embolism in patients suffering from atrial fibrillation (AF). However, the …

Background This study aimed to evaluate the characteristics and clinical outcomes (major
bleeding [MB] and thromboembolic events [TEEs]) of atrial fibrillation (AF) patients with …

Background: Current guidelines and literature suggest apixaban may be used in patients
with severe kidney disease and atrial fibrillation (AF) for stroke and systemic embolism risk …